Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Adc Therapeutics Sa (NY: ADCT )

2.280 -0.030 (-1.30%)
Official Closing Price Updated: 7:00 PM EDT, May 26, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 232,306
Open 2.310
Bid (Size) 2.200 (2)
Ask (Size) 2.750 (1)
Prev. Close 2.310
Today's Range 2.262 - 2.325
52wk Range 1.850 - 10.88
Shares Outstanding 76,721,543
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
ADC Therapeutics Announces Updated Results from LOTIS-2 Trial to be Presented at the European Hematology Association 2023 Hybrid Congress
From ADC Therapeutics SA
Via Business Wire
ADC Therapeutics to Participate in the RBC Capital Markets Global Healthcare Conference
From ADC Therapeutics SA
Via Business Wire

Performance

YTD
-36.49%
-36.49%
1 Month
+17.53%
+17.53%
3 Month
-43.98%
-43.98%
6 Month
-32.94%
-32.94%
1 Year
-69.15%
-69.15%

More News

Read More
ADC Therapeutics Reports First Quarter 2023 Financial Results and Provides Business and Strategy Update
From ADC Therapeutics SA
Via Business Wire
ADC Therapeutics to Host First Quarter 2023 Financial Results Conference Call on May 9, 2023
From ADC Therapeutics SA
Via Business Wire
Earnings Preview: ADC Therapeutics
Via Benzinga
The Latest Analyst Ratings for ADC Therapeutics
Via Benzinga
4 Analysts Have This to Say About ADC Therapeutics
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For April 24, 2023
Via Benzinga
ADC Therapeutics Releases its Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2022
From ADC Therapeutics SA
Via Business Wire
ADC Therapeutics to Participate in the Cowen 43rd Annual Health Care Conference
From ADC Therapeutics SA
Via Business Wire
Stocks That Hit 52-Week Lows On Tuesday
Via Benzinga
ADC Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates
From ADC Therapeutics SA
Via Business Wire
Stocks That Hit 52-Week Lows On Tuesday
Via Benzinga
ADC Therapeutics to Host Fourth Quarter and Year-End 2022 Financial Results Conference Call on February 28, 2023
From ADC Therapeutics SA
Via Business Wire
ADC Therapeutics Announces Pricing of Underwritten Offering by a Selling Shareholder
From ADC Therapeutics SA
Via Business Wire
ADC Therapeutics to Participate in February Investor Conferences
From ADC Therapeutics SA
Via Business Wire
Tesla And Other Big Stocks Moving Lower In Friday's Pre-Market Session
Via Benzinga
TSMC, CommScope Holding And Other Big Stocks Moving Higher On Thursday
Via Benzinga
Why KNOT Offshore Partners Shares Are Trading Lower By Around 38%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
ADC Therapeutics to Participate in the 41st Annual J.P. Morgan Healthcare Conference
From ADC Therapeutics SA
Via Business Wire
ADC Therapeutics Appoints Mohamed Zaki as Chief Medical Officer
From ADC Therapeutics SA
Via Business Wire
Nike, FedEx And Some Other Big Stocks Moving Higher In Today's Pre-Market Session
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
Via InvestorPlace
Why Core Scientific Shares Are Trading Lower By Around 32%; Here Are 26 Stocks Moving Premarket
Via Benzinga
ADC Therapeutics and Sobi Announce European Commission Approval of ZYNLONTA® (loncastuximab tesirine) for the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma
From ADC Therapeutics SA
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.